Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Impact of Ambulatory Physiological Stimulation of the Efferent Limb Prior to Ileostomy Closure on Colorectal Microbiota Composition and Histopathological Findings (STIMIC)

15 juin 2026 mis à jour par: Romina Pena, Hospital Clinic of Barcelona

The STIMIC Trial: A Multicenter Randomized Control Trial Evaluating the Impact of Ambulatory Physiological Stimulation of the Efferent Limb Prior to Ileostomy Closure on Colorectal Microbiota Composition and Histopathological Findings

BACKGROUND Loop ileostomies are a type of stoma frequently used to protect high-risk colorectal anastomoses (surgical reconnection of the intestines), for example following rectal cancer resection. Temporary diversion of intestinal transit does not reduce the risk of anastomotic failure, but it does lower the morbidity and mortality associated with potential pelvic sepsis. Unfortunately, a second surgical procedure is required to restore intestinal continuity, and this carries its own risk of complications, the most common being postoperative ileus (temporary paralysis of bowel motility associated with abdominal distension, absence of bowel movements, nausea, and vomiting), which occurs in up to 20% of cases.

Several strategies have been proposed to reduce this problem, including stimulation of the efferent limb of the ileostomy (the part that is connected to the unused colon). This intervention consists of instilling a substance through the efferent limb of the ileostomy into the colon, simulating natural intestinal transit. It emerged as a harmless alternative aimed at reversing changes in the excluded colon in preparation for restoration of intestinal continuity. Several Spanish studies have investigated this technique, concluding that it is safe and significantly reduces the rate of postoperative ileus, thereby shortening hospital stay. Regarding the mechanism by which this intervention may be effective, there are studies investigating the changes that occur during diversion of intestinal transit:

  1. Histopathology: reduced muscular contractility and the presence of intestinal villi in the efferent intestinal limb and excluded colon, which improve once intestinal flow is restored.
  2. Microbiome: significant loss of microbiota in the defunctionalized colon, which progressively recovers with natural intestinal transit and reintroduction of a fiber-rich diet.

Structural and microbiota-related changes favor the development of diversion colitis, a condition associated with erratic bowel habits once intestinal transit is restored. In an attempt to reverse this condition, several products have been tested for stimulation of the efferent limb of the ileostomy: probiotics, short chain fatty acids, saline solution with a thickening agent, and the patient's own intestinal contents, a well-tolerated and effective technique, in some cases superior to saline-based alternatives.

Overall, the available evidence is of low quality due to the limited number of patients studied and protocol variability. For this reason, we propose the implementation of a protocol for stimulation of the distal ileostomy limb prior to ileostomy closure, either with saline solution and thickening agent (the most widely described technique in the literature) or physiological stimulation using the patient's own intestinal contents.

The protocol consists of several sessions in which the instilled volume is progressively increased. This intervention will be performed on an outpatient basis, once daily, during the two weeks prior to surgery.

This process promotes the onset of bowel movements through the anus, which progressively become more formed and less frequent, approaching a more normal bowel habit. Only minor adverse effects have been described with this technique, including cramp-like abdominal pain in 27.6% of sessions. Recently, a nationwide study confirmed the favorable clinical outcomes following distal ileostomy limb stimulation before ileostomy closure. However, to our knowledge, no studies have evaluated its effect on intestinal microbiota.

HYPOTHESIS Distal limb stimulation of the ileostomy before its closure helps in the recovery of the colorectal microbiome and tissue. This associates with lower postoperative complications, specially postoperative ileus.

OBJECTIVES To gain knowledge regarding changes in intestinal microbiota composition before and after stimulation, in order to better understand recovery of intestinal function following this procedure. We will also analyze outcomes after ileostomy closure following efferent limb stimulation, determining the incidence of postoperative complications, particularly postoperative ileus.

METHODOLOGY

Patients will be randomly assigned to one of three groups:

  1. Control (no intervention other than the usual preoperative protocol)
  2. Stimulation with serum and thickener
  3. Stimulation with own stoma output

Samples will be collected in all patients:

  1. Stoma output
  2. Stool, before stimulation, if performed
  3. Stool, after stimulation, if performed
  4. Stool, a month after surgery

For a group of patients, the ones recruited at Hospital Clínic, rectal biopsies will also be collected before and after stimulation, to compare the effect of the treatment in the colonic tissue. We will collect clinical data during the whole process regarding postoperative complications.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

90

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Romina Pena, MD
  • Numéro de téléphone: +34 617333153
  • E-mail: PENA@clinic.cat

Sauvegarde des contacts de l'étude

  • Nom: Miguel Pera, MD, PhD
  • Numéro de téléphone: 5559 +34 932275400
  • E-mail: PERA@clinic.cat

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion criteria:

  1. Patients 18 yo and older, with a loop ileostomy after colorectal surgery for malignant or benign disease and a barium enema that rules out colorectal anastomotic leak or stenosis.
  2. Patients must be self-sufficient in their stoma care or dispose of assistance by a family member or healthcare provider.
  3. Patients must reside no further than 50km from the hospital and dispose of postoperative home-assistance by a family member or healthcare provider.

Exclusion criteria:

  1. Patients with a terminal ileostomy or a closed distal limb, inaccesible to preoperative stimulation.
  2. Patients with the diagnosis of inflammatory bowel disease.
  3. Patients incapable of comprehending or signing the informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Control
No efferent limb stimulation.
Comparateur actif: Serum stimulation
Efferent limb stimulation with serum and thickener.
The intervention has been described in previous studies, but the investigation of the microbiome changes associated with the obtained clinical results hasn't been described to date. Also, a study with three arms hasn't been published to date.
Autres noms:
  • efferent limb stimulation
  • physiological stimulation
Comparateur actif: Physiological stimulation
Efferent limb stimulation with the patient's own stoma output.
The intervention has been described in previous studies, but the investigation of the microbiome changes associated with the obtained clinical results hasn't been described to date. Also, a study with three arms hasn't been published to date.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Changes in colorectal microbiome before and after efferent limb stimulation prior to stoma closure.
Délai: From enrollment to the end of follow-up at 3 months.
Descriptive analysis of the microbiome profiles of the three groups of patients (control, stimulation with serum, stimulation with own stoma output).
From enrollment to the end of follow-up at 3 months.
Changes in colorectal tissue before and after efferent limb stimulation prior to stoma closure.
Délai: From the time of first biopsy (before stimulation) to the second one (surgery day).
Description of the tissue obtained by biopsy of the rectum, before and after stimulation of the ileostomy.
From the time of first biopsy (before stimulation) to the second one (surgery day).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Postoperative complications after stoma closure.
Délai: From the surgery (ileostomy closure) to 30 days follow-up.
Incidence of postoperative ileus and surgical site infection.
From the surgery (ileostomy closure) to 30 days follow-up.
Functional outcomes after efferent limb stimulation (LARS score)
Délai: From enrollment to the end of follow-up a 3 months.

Description of the funcional (defecatory) outcomes after ileostomy closure.

LARS (Low Anterior Resection Syndrome) score: total score ranges from 0-42 points (0-20 is equivalent no LARS, 21-29 points to minor LARS, and 30-42 to major LARS).

From enrollment to the end of follow-up a 3 months.
Functional outcomes after efferent limb stimulation (Vaizey score)
Délai: From enrollment to the end of follow-up at 3 months.

Description of the funcional (defecatory) outcomes after ileostomy closure.

Vaizey score (also known as the St. Mark's Incontinence Score): total score ranges from 0 (perfect continence) to 24 points (severe incontinence).

From enrollment to the end of follow-up at 3 months.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Romina Pena, MD, Hospital Clinic of Barcelona

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 juin 2026

Achèvement primaire (Estimé)

1 décembre 2027

Achèvement de l'étude (Estimé)

1 mars 2028

Dates d'inscription aux études

Première soumission

26 mai 2026

Première soumission répondant aux critères de contrôle qualité

8 juin 2026

Première publication (Réel)

10 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • HCB/2026/0615

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

All IPD that underlie results in a publication.

Délai de partage IPD

Beginning 1 month and ending 1 year after the publication of results.

Critères d'accès au partage IPD

IPD and supporting information of this study might be accessed by fellow researchers with a future study, related to our published findings. Researchers must submit a request for data sharing by contacting the principal investigator, who will also be the corresponding author in the future published data. The request to access IPD will be reviewed by the principal investigator (Romina Pena).

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • CIF
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner